Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Senderra.

		Pediatric Atopic Dermatitis Enrollment Form			Prescriber:						NPI:			
						sing Physician:		1	NPI:					
SENDERRA		Physici	Physician Offices Call: 855-460-7928		Address:						-	Tax ID:		
Specialty Pharmacy					Phone: Fax:									
1301 E. Arapaho Rd., Ste. 101 F Richardson, TX 75081			Fax: 888-777-5645		Contact:									
This prescription for	m is to be sent & received via fai	ĸ			PATIENT INFORMATION									
Name:						Trans M Trans F Other DOB:				SS#:		SS#:		
Street:						State:			_/	/ZIP:		<del></del>		
Phone: Alt. F			Phone:			English Spanish Other: _					Wt.: Ht.:			
				<b>.</b>					<b>.</b>					
Has the patient	t received a loading dos	e/starter kit?	UYes	Start Date	:/			SHIP TO:		s Home 니	Docto	r's Office Other:	Refills	
			***WEIGHT REQUIRED***											
			Inject 300 mg SQ every 4 weeks (Quantity: 2) <u>set of the set of the </u>											
	300 mg Pre-filled Sy		□ INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) □ MAINTENANCE: Inject 200 mg SQ at day 1 (Quantity: 2) ***Intended for <u>patients age 6 years to 17 years</u>											
Dupixent®	□ 300 mg Pen*	(C	MAIN I ENANCE: Inject 300 mg SQ every 4 weeks starting at day 29 (Quantity: 2)											
			□ INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2)											
			□ MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight ≥ 60 kg/132 lbs***											
		🗖 Inje	□ Inject 200 mg SQ every 4 weeks (Quantity: 2) <sup>***</sup> Intended for <u>patients age 6 months to 5 years</u> <u>old weight 5 kg/11 lbs to &lt;15 kg/33 lbs***</u>											
	□ 200 mg Pre-filled Sy □ 200 mg Pen*	ringe 🛛 INI	INITIAL: Inject 400 mg SQ at day 1 (Quantity: 2)  **Intended for weight 30 kg/66 lbs to < 60 kg/132											
	_ 200 mg r en		MAINTENANCE: Inject 200 mg SQ every other week starting at day 15 (Quantity: 2)											
	□ 2% Ointment 60 gm*													
Eucrisa®	2% Ointment 100 gm		pply a thin layer to affected area(s) twice a day (Quantity: 1 tube)											
Opzelura™	□ 1.5 % Cream 60 gm	* 🛛 Ap	Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)											
	***WEIGHT REQUIRED***													
Rinvoq®	□       15 mg Tablet*       □       Take 15 mg PO once daily (Quantity: 30)       ****Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs***         □       0.0 mg Tablet*       □       Take 20 mg PO once daily (Quantity: 30)       ****Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs if													
	□ 30 mg Tablet*	a Take 50 mg PO once daily (Qualitity: 50) adequate response was not achieved with 15 mg daily dose***									<u> </u>			
*Dupixent pens FDA approved for ages 12 and over *Eucrisa FDA approved for ages 3 months and over *Opzelura FDA approved for ages 12 years and over *Rinvoq FDA approved for ages 12 years and over														
<mark>*** </mark>	PLEASE FAX COPY OF I	PRESCRIPTI		ICAL CAR		AL INFORMATI <mark>F AND BACK, A</mark>		ELL AS AN		AL NOTES	REG	ARDING THERAPY***		
PREVIOUS TH	ERAPIES: Tried a	& Failed (Dur			ot Tolerate			indication:				L L		
Methotrexate				)			_			AAA AAA				
		· · · · · · · · · · · · · · · · · · ·	)						-					
Tacrolimus			)	)				-						
		· · · · · · · · · · · · · · · · · · ·	) )	/				· · · · · · · · · · · · · · · · · · ·				XM XK		
			)									Affected Areas		
			/							Face 🛛	Feet	Groin Hand	ds	
			led (Duration): No			ot Tolerated: Contraindication:				Nails 🛛				
UVA /UVB [ Patient cannot afford Pho		Photosensitiv	)			Skin Cancer Distance from Office				Scoring tool used				
												VI		
L20.9 Atopic Dermatitis (Moderate to Severe)       Other:														
Date of Diagnosis:// Allergies:														
Active TB is ruled out:        Yes     No     Date: / /     Hep B ruled out/treated:     Yes     No     Date: / /														
Additional Clin	Additional Clinical Information:													
INJECTION TRAINING														
Prescription training Physician's office to provide injection training Senderra to coordinate injection training														
	PRESCRIBER SIGNATURE <u>To Prescriber:</u> By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay anisteness foundations													
assistance foundations.  Prescriber: / /														
	for is intended to be delivered as	ly to the named	addrosse -	It contains					icologuro um			you are not the nemod address		
	tax is intended to be delivered or ate, distribute, or copy this fax.											you are not the named addressee, y	,ou	